Business Wire

First-in-Human Trial of New Immunotherapy Approach Shows Efficacy in Antibiotic Resistance

Del

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, announced today its first-in-human trial of new immunotherapy approach has shown efficacy in antibiotic-resistant bacteria based on a recent paper published online in Clinical Infectious Diseases .

“This study provides the first clinical evidence showing the human polyclonal antibody therapeutic–produced from our natural DiversitAb immunotherapy platform–is safe, and provides an option for recalcitrant infection resistant bacteria where antibiotics and multiple other therapies were ineffective,” said Eddie J. Sullivan, PhD, SAB Biotherapeutics president and CEO.

“This is an important step in furthering the development of this platform technology in infectious disease, including anti-microbial resistance,” he continued.

The patient.

The trial, conducted at Brigham and Women's Hospital, involved a patient who suffered from a chronic infection caused by antibiotic-resistant bacteria. Mycoplasma hominis can be an infectious pathogen in immunosuppressed individuals. The patient was diagnosed with M. hominis septic polyarthritis in 2009 and was treated with multiple courses of antibiotics with no improvement. A target-specific human polyclonal antibody was pursued as a potentially more effective therapeutics strategy.

The science.

SAB’s new immunotherapy approach–The DiversitAb platform–leverages transchromosomal (Tc) bovine™ that have been genetically designed to produce fully human polyclonal antibodies (IgG) in response to a bacteria, virus or toxin. To create the targeted treatment, SAB vaccinated a Tc bovine with inactivated isolates of the patient’s bacteria (M. hominis). After 10 days the antibodies began circulating in the bovine blood stream and were harvested in plasma over several weeks.

The treatment.

The plasma was purified in the company’s cGMP manufacturing facilities to isolate the antibodies–designated SAB-136. The patient–the first to be treated with human polyclonal IgG harvested from Tc bovine–received infusions to combat the infection.

The result.

After one year, the high-dose therapy resulted in reduced M. hominis burden and improved clinical parameters. The infusions were well tolerated and with no significant adverse events. Safety was assessed with laboratory values, physical exam and subjective reports. Therapeutic efficacy was evaluated with samples collected from the primary infection site, and laboratory studies to monitor inflammation as well as a patient journal.

“This research demonstrates the potential for expanding treatment for immune deficient patients suffering from infections, which may have low coverage in current antibody replacement therapies,” said Duane Wesemann, MD, PhD, a physician in the Rheumatology, Immunology and Allergy department at BWH and an Assistant Professor of Medicine, Harvard Medical School and principal investigator on the study.

“The use of DiversitAb platform begins to explore the relevancy for other patient populations in the setting of chronic, multi-drug resistant infections or viral infections for which there is no effective treatment or prevention strategy,” he added.

SAB’s first two immunotherapies targeting seasonal influenza and MERS-CoV are in clinical trials, with other infectious disease, oncology and autoimmune targets in development.

“With the advancements of modern medicine–and even recent immunotherapies–there are still many human health conditions without solutions,” concluded Sullivan. “Our hope is that our platform can provide a new rapid response and effective treatment for many of these patients.”

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, S.D. is a clinical-stage, biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.

Contact information

SAB Biotherapeutics, Inc.
Melissa Ullerich, +1 605-695-8350
media@sabbiotherapeutics.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Octapharma Share Promising Preclinical Data for SubQ-8, a Novel Subcutaneous Recombinant FVIII, at WFH 201828.5.2018 07:58Pressemelding

Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. SubQ-8, currently under development, is a recombinant FVIII from a human cell line for subcutaneous administration. SubQ-8 is based on Octapharma’s human cell line-derived rFVIII product simoctocog alpha combined with a fragment of the von Willebrand Factor (VWF) protein, and harnesses the protective power of VWF in an innovative approach to facilitate transportation of FVIII into the circulation. Regular intravenous administration of FVIII poses a considerable burden to people with haemophilia A and their families. Alternative routes of administration may help to alleviate some of this burden and improve adherence to prophylaxis therapy. This symposium, entitled ‘Taking FVIII into the future: The development of subcutaneous recombinant human FVIII for the treatment of haemophilia A’, reviewed the challenge

Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress28.5.2018 07:57Pressemelding

Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. Nuwiq® is a 4th generation human cell line-derived recombinant FVIII (rFVIII) approved for the prevention and treatment of bleeding episodes in patients of all ages with haemophilia A. The symposium, entitled ‘Going further to meet clinical needs: New data with Nuwiq ® ▼ (simoctocog alfa; human-cl rFVIII) from clinical trials and real-world experience’, focused on the challenges within the current haemophilia treatment landscape and opportunities to improve patient care. The symposium, chaired by Craig Kessler, addressed the reality that no two haemophilia A patients are the same. An optimal treatment approach should therefore reflect each individual patient’s profile. Striving towards this goal, two approaches to using pharmacokinetic (PK) data to personalise prophylaxi

Gemalto Announces Collaboration with Qualcomm Technologies to Integrate eSIM Innovation into the Snapdragon Mobile PC Platform28.5.2018 05:00Pressemelding

Gemalto announces a new collaboration that will see its advanced mobile connectivity solutions integrated with Qualcomm® Snapdragon™ mobile PC platform, a product by Qualcomm Technologies Inc., a subsidiary of Qualcomm Incorporated. This paves the way for iSIM commercialization on a growing range of Always Connected PCs, laptops and tablets. The effort will support the integration of Gemalto’s eSIM technology and remote subscription management solutions, with the new Secure Processing Unit (SPU) on the Snapdragon mobile PC platform. As a result, this innovation will provide seamless LTE and forthcoming 5G connection, extended battery life, and a foundation for consumer applications such as online payments, transport ticketing and authentication to cloud services. This initiative represents the first time an eSIM will be integrated with processing platforms designed to power Always Connected PCs and similar consumer devices. Providing benefits for industry players: OEMs optimize their b

CES Asia 2018 Announces Innovation Award Honorees27.5.2018 20:00Pressemelding

The Consumer Technology Association (CTA) today announced its Innovation Awards Honorees for CES Asia 2018. Now in its second year, the CES Asia Innovation Awards Program celebrates outstanding product design and engineering in brand-new consumer technology products from CES Asia exhibitors. The program recognizes groundbreaking technologies across 20 product categories, including first-time category artificial intelligence (AI) located primarily in SNIEC, Hall N3 at CES Asia 2018. Additional areas of recognition include augmented reality (AR), virtual reality (VR), content, mobile, vehicle tech, smart home, digital health, wearables and more. CES Asia is a global show with exhibiting companies originating from 23 countries, regions and territories. An elite panel of judges with industry expertise in product design and engineering deliberated on the honorees for this prestigious awards program. The honored products excelled in five criteria: engineering, aesthetics, function and user v

FCF: Greenpeace Allegations Unfair and Deceptive26.5.2018 18:02Pressemelding

FCF Fishery, Co. President Max Chou today released the following statement regarding recent misleading Greenpeace human rights abuse allegations made against the company: “We realize that as one of the world’s largest marine products integrated supply chain service providers with more than 30 subsidiaries, fishing bases, and shipping agents around the world, we are a prime target for organizations seeking to garner publicity and those not fully aware of the latest development and improvements that are currently taking place in the fishery industry. However, in their efforts to curb egregious human rights abuses, we believe it is unfair and deceptive to lump our company in with those who condone cruelty and neglect of their laborers. “Although we recognize the meaningful work of Greenpeace in exposing and eliminating human trafficking and sustainability abuses, we are equally disappointed that they are implicating FCF in old incidents and cases that have since been in all instances addr

NBC Universal, Havas Group and Endemol Shine Discuss a Future with AI, Blockchain and VR at IBC201825.5.2018 18:20Pressemelding

As is fitting for the home of technical invention and innovation, IBC2018 will present a broad range of ambitious and timely elements to engage, inform and inspire content creators and owners from around the world that will visit the RAI, Amsterdam from 13-18 September 2018. The must-attend event includes fresh inspiring conference themes that will focus on innovative new platforms, audience engagement and interaction/immersion, as well as a wide-ranging exhibition that will encompass all the latest technologies from AI and VR to advanced cloud-based workflows. Registration for IBC2018 is now open at: https://ibc.itnint.com/IBC18/Online/RegLogin.aspx “The media landscape is evolving at an unprecedented rate, with new platforms, technologies and even new realities at our disposal that offer greater opportunities for content innovation and audience engagement,” said Michael Crimp, CEO, IBC. “IBC is preparing an outstanding programme of conference sessions, forums and exhibition features